There’s a New Drug for a Specific Late-Stage Lung Cancer
The FDA has finally given its nod of approval to Iressa (getfinitib) developed by AstraZeneca to treat and delay the progression of the disease for patients with metastatic non-small cell lung cancer (NSCLC) with EGFR (epidermal growth factor receptor) mutations.
Posted On Jul 14 2015